Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Annovis BioEli Lilly
Last price
$0.99$1,257.03
Currency
USD
USD
$42M$1.1T
-42.20
-$1.79$29.79
1.240.45
0$6.69
00.55%
Sector
HealthHealth
Employees
-50,000
Ticker
$ANVS$LLY
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ANVS or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.